Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 89 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

6%

5 trials in Phase 3/4

Results Transparency

0%

0 of 12 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

64Total
Not Applicable (48)
P 1 (4)
P 2 (7)
P 3 (3)
P 4 (2)

Trial Status

Recruiting46
Not Yet Recruiting22
Completed12
Enrolling By Invitation5
Active Not Recruiting3
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (89)

Showing 20 of 20 trials
NCT07463209Not ApplicableRecruiting

Integrating New Skills Into Diabetes Education With CGM

NCT07732777Not ApplicableRecruiting

AI-Assisted Remote Insulin Pump Optimization in T1DM

NCT06752369Not ApplicableRecruitingPrimary

Adapting Single Sessions Interventions for Type 1 Diabetes

NCT06967701Not ApplicableRecruitingPrimary

Building and Sustaining Exercise Habits for Adults With Type 1 Diabetes

NCT07599982Not ApplicableRecruitingPrimary

Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes

NCT07612475Not Yet RecruitingPrimary

Universal Type 1 Diabetes Screening in Pediatrics

NCT07667504Not ApplicableRecruitingPrimary

Dietary Approaches for the Management of Overweight and Obesity in Type 1 Diabetes

NCT07699380Phase 2RecruitingPrimary

METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)

NCT06883344Not ApplicableRecruitingPrimary

Automated Insulin for Management of Intrapartum Glycemia

NCT07118098RecruitingPrimary

INNODIA Family & Friends Early-Stage T1D Detection Protocol

NCT06694558Recruiting

Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease

NCT07683026Phase 2Not Yet RecruitingPrimary

Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo

NCT06624046Not ApplicableRecruitingPrimary

Circadian Mechanisms, Glucose, and CV Risks in T1D

NCT07670650Phase 3Not Yet RecruitingPrimary

PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study

NCT07666789RecruitingPrimary

Efficacy of Islet Re-transplantation After Failure of Beta-cell Replacement

NCT07663136Not ApplicableNot Yet Recruiting

Finding Immune Nascent Type 1 Diabetes

NCT06626347Not ApplicableCompletedPrimary

Telemedicine for Reach, Education, Access, and Treatment for Diabetes Self-Management Education and Support

NCT07507708Not ApplicableRecruitingPrimary

Insulin Delivery With Self-Adjusting Closed-Loop and Behavioral Glycemic Control Enhanced by Prediction

NCT07011147Not ApplicableRecruitingPrimary

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

NCT07578584Phase 1RecruitingPrimary

A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or Obesity

Scroll to load more

Research Network

Activity Timeline